title: A subpopulation of CD24⁺ cells in colon cancer cell lines possess stem cell characteristics.
abstract: Cancer stem cells (CSCs) have been shown to contribute to the resistance and relapse in a range of cancer types such as breast cancer and glioma. However, colon cancer stem cells remain poorly characterized. Here we reported that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibited cancer stem cell-like characteristics. Using flow cytometry candidate CSCs markers were selected after initial screening of known CSCs markers from other types of cancer on colon cancer cell lines HCT116, SW480 and HT29. CD24 was expressed in the minority of bulk cell population of HCT116 and SW480 cell lines. Moreover, functional tests demonstrated that CD24+ cells exhibited enhanced chemotherapy-resistance, self-renewal and tumorigenic capacity both in vitro and in vivo, compared to CD24- subpopulations. These results suggest that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibits CSCs like characteristics, and represents a nice model to study and develop effective strategies to overcome chemo-resistance and relapse of colon cancer.
authors.affiliation: Colorectal Surgery Department, 6th Hospital of Sun Yat-sen University, Guangdong, China.
authors.forename: J
authors.initials: J
authors.lastname: Ke
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: X
authors.initials: X
authors.lastname: He
authors.forename: L
authors.initials: L
authors.lastname: Lian
authors.forename: Y
authors.initials: Y
authors.lastname: Zou
authors.forename: X
authors.initials: X
authors.lastname: He
authors.forename: H
authors.initials: H
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Luo
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: P
authors.initials: P
authors.lastname: Lan
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism; D051927:CD24 Antigen / Q000378:metabolism*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005434:Flow Cytometry; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology* / Q000637:transplantation; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D051927:CD24 Antigen; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil